{"nctId":"NCT01045161","briefTitle":"Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)","startDateStruct":{"date":"2009-03"},"conditions":["Chronic Obstructive Pulmonary Disease"],"count":544,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Aclidinium bromide"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Aclidinium bromide"]},{"label":"3","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Aclidinium bromide","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A diagnosis of stable moderate to severe COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, 2008; postbronchodilator FEV1/FVC \\< 70%, and postbronchodilator FEV1 â‰¥ 30% and \\< 80% predicted\n* Current or former cigarette smokers\n\nExclusion Criteria:\n\n* Patients who have been hospitalized for an acute COPD exacerbation within 3 months before the first visit\n* Respiratory tract infection or COPD exacerbation in the 6 weeks before Visit 1\n* Patient with any clinically significant respiratory conditions other than COPD, cardiovascular conditions or mental illness\n* History or presence of asthma verified from medical records\n* Chronic use of oxygen therapy greater than or equal to 15 hours per day\n* Patient with uncontrolled infection due to HIV and/or active hepatitis\n* Patients with a history of hypersensitivity reaction to inhaled anticholinergics\n* Patients with clinically significant cardiovascular conditions, including myocardial infarction during the previous 6 months, newly diagnosed arrhythmia within the previous 3 months, unstable angina, unstable arrhythmia that had required changes in pharmacological therapy or other intervention.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part A: Morning Predose (Trough) Forced Expiratory Volume in 1 Second (FEV1)","description":"Change from baseline in Trough forced expiratory volume in 1 second before the morning dose of aclidinium bromide, Last Observation Carried Forward (LOCF)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.008","spread":"0.015"},{"groupId":"OG001","value":"0.043","spread":"0.015"},{"groupId":"OG002","value":"0.064","spread":"0.016"}]}]}]},{"type":"SECONDARY","title":"Part A: Peak Forced Expiratory Volume in 1 Second (FEV1)","description":"Change from baseline in peak FEV1 at week 12, Last Observation Carried Forward (LOCF)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.087","spread":"0.018"},{"groupId":"OG001","value":"0.202","spread":"0.018"},{"groupId":"OG002","value":"0.212","spread":"0.018"}]}]}]},{"type":"PRIMARY","title":"Part B: Morning Predose (Trough) FEV1","description":"Change from Baseline in Morning Pre-dose (trough) Forced Expiratory Volume in 1 Second (FEV1) at Week 52, Lost Observation Carried Forward (LOCF)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.045","spread":"0.021"},{"groupId":"OG001","value":"0.029","spread":"0.020"},{"groupId":"OG002","value":"0.048","spread":"0.021"}]}]}]},{"type":"SECONDARY","title":"Part B: Peak FEV1","description":"Change from Baseline in Peak FEV1 (L) at Week 52, Last Observation Carried Forward (LOCF)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.185","spread":"0.023"},{"groupId":"OG001","value":"0.176","spread":"0.023"},{"groupId":"OG002","value":"0.172","spread":"0.023"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":182},"commonTop":["COPD exacerbation","Upper respiratory tract infection","Nasopharyngitis"]}}}